These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31337255)

  • 21. FBXW7-mediated ERK3 degradation regulates the proliferation of lung cancer cells.
    An HJ; Lee CJ; Lee GE; Choi Y; Jeung D; Chen W; Lee HS; Kang HC; Lee JY; Kim DJ; Choi JS; Cho ES; Choi JS; Cho YY
    Exp Mol Med; 2022 Jan; 54(1):35-46. PubMed ID: 35022544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.
    Koo J; Wu X; Mao Z; Khuri FR; Sun SY
    J Biol Chem; 2015 May; 290(22):14120-9. PubMed ID: 25897075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenovirus E1A inhibits SCF(Fbw7) ubiquitin ligase.
    Isobe T; Hattori T; Kitagawa K; Uchida C; Kotake Y; Kosugi I; Oda T; Kitagawa M
    J Biol Chem; 2009 Oct; 284(41):27766-27779. PubMed ID: 19679664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver.
    Onoyama I; Suzuki A; Matsumoto A; Tomita K; Katagiri H; Oike Y; Nakayama K; Nakayama KI
    J Clin Invest; 2011 Jan; 121(1):342-54. PubMed ID: 21123947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
    Li N; Lorenzi F; Kalakouti E; Normatova M; Babaei-Jadidi R; Tomlinson I; Nateri AS
    Oncotarget; 2015 Apr; 6(11):9240-56. PubMed ID: 25860929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FBXW7 inactivation induces cellular senescence via accumulation of p53.
    Gong L; Cui D; Liu D; Shen X; Pan H; Xiong X; Zhao Y
    Cell Death Dis; 2022 Sep; 13(9):788. PubMed ID: 36104351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abrogation of FBW7α-dependent p53 degradation enhances p53's function as a tumor suppressor.
    Tripathi V; Kaur E; Kharat SS; Hussain M; Damodaran AP; Kulshrestha S; Sengupta S
    J Biol Chem; 2019 Sep; 294(36):13224-13232. PubMed ID: 31346036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Highs and Lows of FBXW7: New Insights into Substrate Affinity in Disease and Development.
    de la Cova CC
    Cells; 2023 Aug; 12(17):. PubMed ID: 37681873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis.
    Onoyama I; Tsunematsu R; Matsumoto A; Kimura T; de Alborán IM; Nakayama K; Nakayama KI
    J Exp Med; 2007 Nov; 204(12):2875-88. PubMed ID: 17984302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of FBXW7 in Gynecologic Malignancies.
    Di Fiore R; Suleiman S; Drago-Ferrante R; Subbannayya Y; Suleiman S; Vasileva-Slaveva M; Yordanov A; Pentimalli F; Giordano A; Calleja-Agius J
    Cells; 2023 May; 12(10):. PubMed ID: 37408248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of SCF ubiquitin ligases by engineered ubiquitin variants that target the Cul1 binding site on the Skp1-F-box interface.
    Gorelik M; Orlicky S; Sartori MA; Tang X; Marcon E; Kurinov I; Greenblatt JF; Tyers M; Moffat J; Sicheri F; Sidhu SS
    Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3527-32. PubMed ID: 26976582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The FBXW7-SHOC2-Raptor Axis Controls the Cross-Talks between the RAS-ERK and mTORC1 Signaling Pathways.
    Xie CM; Tan M; Lin XT; Wu D; Jiang Y; Tan Y; Li H; Ma Y; Xiong X; Sun Y
    Cell Rep; 2019 Mar; 26(11):3037-3050.e4. PubMed ID: 30865892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The ubiquitin ligase FBXW7 targets the centriolar assembly protein HsSAS-6 for degradation and thereby regulates centriole duplication.
    Badarudeen B; Gupta R; Nair SV; Chandrasekharan A; Manna TK
    J Biol Chem; 2020 Apr; 295(14):4428-4437. PubMed ID: 32086376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
    Urick ME; Bell DW
    Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FBXW7/hCDC4 is a general tumor suppressor in human cancer.
    Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
    Cancer Res; 2007 Oct; 67(19):9006-12. PubMed ID: 17909001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FBXW7 Facilitates Nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4.
    Zhang Q; Karnak D; Tan M; Lawrence TS; Morgan MA; Sun Y
    Mol Cell; 2016 Feb; 61(3):419-433. PubMed ID: 26774286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MYC is a critical target of FBXW7.
    Sato M; Rodriguez-Barrueco R; Yu J; Do C; Silva JM; Gautier J
    Oncotarget; 2015 Feb; 6(5):3292-305. PubMed ID: 25669969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fbw7α and Fbw7γ collaborate to shuttle cyclin E1 into the nucleolus for multiubiquitylation.
    Bhaskaran N; van Drogen F; Ng HF; Kumar R; Ekholm-Reed S; Peter M; Sangfelt O; Reed SI
    Mol Cell Biol; 2013 Jan; 33(1):85-97. PubMed ID: 23109421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential regulation of FBXW7 isoforms by various stress stimuli.
    Sionov RV; Netzer E; Shaulian E
    Cell Cycle; 2013 Nov; 12(22):3547-54. PubMed ID: 24091628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
    Baxter JS; Brough R; Krastev DB; Song F; Sridhar S; Gulati A; Alexander J; Roumeliotis TI; Kozik Z; Choudhary JS; Haider S; Pettitt SJ; Tutt ANJ; Lord CJ
    Mol Oncol; 2024 Feb; 18(2):369-385. PubMed ID: 37866880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.